Granules India, a low profile small-cap Pharma company, has been put on the center stage by being proclaimed as a potential 100-bagger in the Motilal Oswal Wealth Creation Study report. We need to urgently come to grips with the stock because there may be mega bucks in store for us
Subscribe to Blog via Email
Join 463 other subscribers
- Piramal Pharma is a conviction pick for Target Price of ₹210 (42% upside)Piramal Pharma is a conviction pick. Co is at critical inflection point. Overall improvement is expected as CDMO momentum continues. Complex Hospital generics is a niche & steady business. Margin is improving. Balance sheet stress is waning. TP ₹210 (42%) https://rakesh-jhunjhunwala.in/piramal-pharma-is-at-critical-inflection-point-and-expect-overall-improvement-as-the-cdmo-momentum-continues-buy-for-target-price-of-%e2%82%b9210-42-upside-icici-direct/... Piramal Pharma is a conviction pick for Target Price of ₹210 (42% upside)
- L&T Finance has consistently delivered strong growth. Target Price ₹230 (25%)L&T Finance has consistently delivered strong growth. It has invested in process automation, security & customer journeys. This, along with partnerships with e-aggregators, should lead to a stronger & more sustainable retail loan growth. TP ₹230 (25%)... L&T Finance has consistently delivered strong growth. Target Price ₹230 (25%)
- Dolly Khanna has invested in 1.63% of Emkay Global. Investment is worth ₹6.65 CrDolly Khanna has invested in 1.63% of Emkay Global. Investment is worth ₹6.65 Cr. Co is a play on broking, investment banking & wealth management. Promoters hold 75%. In FY 24, PMS+AIF AUMs increased by 38% YoY to ₹9,023 mn. Wealth AUMs increased by 42% YoY to ₹31,772 mn. ... Dolly Khanna has invested in […]
Recent Posts
- Pre Budget Expectations 2024-25 by HDFC Securities
- Piramal Pharma is at critical inflection point and expect overall improvement as the CDMO momentum continues. BUY for target price of ₹210 (42% upside): ICICI Direct
- L&T Finance Earnings in line; strong retail momentum continues NIM improves ~15bp QoQ; asset quality stable. Target Price ₹230 (25% upside): Motilal Oswal
- Downgrade Defence Sector on Super Rich Valuations: Nirmal Bang
- JB Pharma offers a healthy cocktail of a robust domestic franchise, niche CMO presence and measured exports strategy, Buy for target price of ₹2025 (15% upside): Kotak Securities
Recent Comments